| 1 |
33527177 | Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. | 2021 May |
1 |
| 2 |
34023008 | Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. | 2021 Jun 5 |
1 |
| 3 |
34023009 | Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. | 2021 Jun 5 |
1 |
| 4 |
34471993 | Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. | 2021 Oct |
1 |
| 5 |
32539713 | JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. | 2020 Jun 15 |
2 |
| 6 |
30394138 | Upadacitinib for the treatment of rheumatoid arthritis. | 2019 Jan |
1 |
| 7 |
31375130 | Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. | 2019 Aug 2 |
1 |